​

OnKure Therapeutics Stock (NASDAQ:OKUR)

OwnershipFinancialsChart
OnKure Therapeutics by TradingView

Previous Close

$4.22

52W Range

$1.91 - $5.38

50D Avg

$4.16

200D Avg

$3.54

Market Cap

$56.34M

Avg Vol (3M)

$302.35K

Beta

0.27

Div Yield

-

OKUR Company Profile

OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

45

IPO Date

Apr 08, 2021

Website

OKUR Performance

OKUR Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-62.95M$-54.39M$-36.93M
Net Income-$-52.67M$-35.31M
EBITDA$-62.95M$-51.71M$-34.75M
Basic EPS$-4.40$-3.95$-2.65
Diluted EPS$-4.40$-3.95$-2.65

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
MRSNMersana Therapeutics, Inc.
FGENFibroGen, Inc.
TPSTTempest Therapeutics, Inc.
BRNSBarinthus Biotherapeutics plc
XLOXilio Therapeutics, Inc.
PDSBPDS Biotechnology Corporation
ALGSAligos Therapeutics, Inc.